Abstract: Among women, breast cancer is the most commonly diagnosed cancer worldwide. Although adjuvant chemotherapy, radiotherapy, targeted therapy, and endocrine therapy have significantly reduced the mortality risk, some patients can not benefit from existing treatments, especially those with advanced breast cancer. With the rapid progression of immunotherapy, substantial advances have been made in breast cancer translational studies. From basic research to clinical practice, China has recently achieved outstanding accomplishments in the field of breast cancer-targeting immunotherapy with respect to molecular target discovery, drug invention, and clinical trial design. This review will introduce the recent achievements of the breast cancer translational research in China regarding therapeutic targets, predictive markers, and immunotherapy therapeutic methods.